2171 Stock Overview
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CARsgen Therapeutics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.33 |
| 52 Week High | HK$12.64 |
| 52 Week Low | HK$3.73 |
| Beta | 0.42 |
| 1 Month Change | -12.62% |
| 3 Month Change | 15.37% |
| 1 Year Change | -56.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.23% |
Recent News & Updates
Shareholder Returns
| 2171 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 18.4% | 8.1% | 3.5% |
| 1Y | -56.9% | -40.2% | -9.9% |
Price Volatility
| 2171 volatility | |
|---|---|
| 2171 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2171's share price has been volatile over the past 3 months.
Volatility Over Time: 2171's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 516 | Zonghai Li | www.carsgen.com |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.
CARsgen Therapeutics Holdings Limited Fundamentals Summary
| 2171 fundamental statistics | |
|---|---|
| Market cap | HK$3.07b |
| Earnings (TTM) | -HK$807.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs 2171 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2171 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥747.79m |
| Earnings | -CN¥747.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.1% |
How did 2171 perform over the long term?
See historical performance and comparison